Bridger Management Files Form 144 Notice to Sell $14.4M in Teva Pharmaceutical ($TEVA)

Executive Summary

On September 18, 2026, Bridger Management, LLC filed a Form 144 notice disclosing an intention to sell 367,600 Ordinary Shares of Teva Pharmaceutical Industries Ltd ($TEVA) through Apex Clearing Corporation, with an aggregate market value of $14,406,244.00 (~$39.19 per share).

Insider Background & Affiliation

Bridger Management, LLC serves as the investment manager of Swiftcurrent Master Fund, Ltd., which directly holds the shares covered by this filing. Notably, Roberto Mignone, the Founder and Managing Partner of Bridger Management, serves as a member of the Board of Directors of Teva Pharmaceutical Industries Ltd. Consequently, transactions by Bridger Management carry corporate insider relevance.

Transaction Details

• Security: Ordinary Shares (NYSE: TEVA)
• Shares Proposed for Sale: 367,600
• Aggregate Market Value: $14,406,244.00
• Shares Outstanding: 1,166,292,643
• Transaction Size vs. Outstanding: ~0.031%
• Original Acquisition: Open market purchases executed on May 9, 2018
• Past 3 Months Activity: Nothing to report

Market & Trading Significance

While the total proceeds ($14.41M) represent a meaningful capital liquidation, the transaction accounts for a modest percentage (~0.03%) of Teva's broad share float (1.17B shares outstanding). Because the shares originated from open-market purchases dating back to 2018, this proposed sale reflects long-term portfolio rebalancing rather than short-term opportunism, leading to an overall Medium trading significance rating.